The efficacy and adverse reactions of DCF and FOLFOXs regimens for patients with advanced gastric cancer in China: a meta-analysis

Minxue Chen; Yong Fan; Zhiqiang Zhao; Yuanhua Nie; Fulin Ma; Xingang Wang; Qiuya Wei; Yuebin Wang; Boxiong Kang; Yongyong Liu; Hao Chen; Chen Wang

doi:10.21037/tcr-19-2564

The efficacy and adverse reactions of DCF and FOLFOXs regimens for patients with advanced gastric cancer in China: a meta-analysis

Transl Cancer Res. 2020 Jul;9(7):4279-4289. doi: 10.21037/tcr-19-2564.

Authors

Minxue Chen^#¹, Yong Fan^#¹, Zhiqiang Zhao¹, Yuanhua Nie¹, Fulin Ma¹, Xingang Wang¹, Qiuya Wei¹, Yuebin Wang¹, Boxiong Kang¹, Yongyong Liu¹, Hao Chen², Chen Wang¹

Affiliations

¹ Department of Minimally Invasive Surgery, The Second Hospital of Lanzhou University, Lanzhou, China.
² Department of Oncology Surgery, The Second Hospital of Lanzhou University, Lanzhou, China.

^# Contributed equally.

Abstract

Background: Gastric cancer is a malignant tumor originating from the gastric mucosal epithelium, ranking fourth in the incidence of male malignant tumors and third in mortality rate. The aim of this study is to investigate the efficacy and adverse reactions of DCF and FOLFOXs regimens in the treatment of advanced gastric cancer.

Methods: Relevant prospective clinical controlled studies were retrieved from WanFang Data, CBM, CNKI, PubMed, The Cochrane Library and Embase databases and meta-analysis was performed using RevMan 5.3 software.

Results: The effective rates of DCF group and FOLFOXs group were basically the same (RR 1.06, 95% CI: 0.92-1.23, P=0.41). The incidence of nausea and vomiting (RR 1.36, 95% CI: 1.15-1.60), anemia (RR 2.04, 95% CI: 1.55-2.68), thrombocytopenia (RR 1.52, 95% CI: 1.15-2.01) and leukopenia (RR 1.70, 95% CI: 1.44-2.01) with FOLFOXs regimen were significantly lower than DCF regimen, while the incidence of sensory neurotoxicity was significantly higher than DCF regimen (RR 0.53, 95% CI: 0.38-0.74). There were no significant differences in efficacy, ORR and DCR between different doses in the FOLFOXs group (P=0.233).

Conclusions: The efficacy of FOLFOXs regimen was comparable to that of DCF regimen in the treatment of advanced gastric cancer, but the incidence of adverse reactions was significantly lower, and there were no significant differences between different therapeutic doses.

Keywords: Advanced gastric cancer; DCF regimen; FOLFOXs regimen; adverse reactions; efficacy.